The Experts
of AP-CHAAI
The AP-CHAAI Steering Committee
The AP-CHAAI Steering Committee is comprised of leading experts from across the Asia Pacific region in fields including aging, immunization, adult vaccines, infectious disease, and health economics. The Committee provides strategic guidance, ensures regional relevance, and brings multidisciplinary expertise to advance AP-CHAAI’s mission of strengthening healthy aging and adult immunization across the region.
In addition to this leadership role, Steering Committee members also contribute to more targeted workstreams through one or more of AP-CHAAI’s three working groups: the Surveillance Working Group, the Prevention & Awareness Working Group, and the Vaccine Policy Working Group.
AP-CHAAI Steering Committee Members
Surveillance Working Group
Dr. Tikki Pangestu
Visiting Professor, Yong Loo Lin School of Medicine, National University of Singapore
Dr. Norio Ohmagari
Deputy Director General of Center Hospital: Infectious Diseases and Health Security Director, Disease Control and Prevention Center
Dr. Po-Ren Hsueh
Vice Dean, College of Medicine, China Medical University
Dr. Peter Richmond
Professor, Head of Division, UWA Medical School, Paediatrics
Dr. Hitoshi Oshitani
Professor, Department of Virology of Tohoku University Graduate School of Medicine
Dr. Yee-Chun Chen
Division Director of Infectious Disease, NTU Hospital, Taiwan
Prevention & Awareness Working Group
Dr. Ian Barr
Deputy Director, WHO Collaborating Centre for Reference and Research on Influenza; Professor, Department of Microbiology & Immunology, University of Melbourne
Dr. John Beard
Irene Diamond Professor of Epidemiology and Health Policy and Management, and Director, International Longevity Center-USA, Columbia University
Ms. Janice Chia
Founder & Managing Director, Ageing Asia, Singapore Founder, ASPIRE55, Singapore
Dr. Lutz Beckert
Associate Dean, Medical Education, University of Otago, Christchurch
Ms. Naomi Sakurai
President, Cancer Solutions
Ms. Yui Kohno
Manager, HGPI
Dr. Jane Barratt
Independent Consultant and Global Advisor, International Federation on Ageing
Vaccine Policy Working Group
Dr. Heidi J. Larson
Director, The Vaccine Confidence Project at the London School of Hygiene & Tropical Medicine (U.K.)
Ms. Janice Chia
Founder & Managing Director, Ageing Asia, Singapore Founder, ASPIRE55, Singapore
Dr. Norio Ohmagari
Deputy Director General of Center Hospital: Infectious Diseases and Health Security Director, Disease Control and Prevention Center
Dr. John S. Tam
Honorary Professor, The Hong Kong Polytechnic University, Director, Asia Pacific Alliance for the Control of Influenza
Ms. Peta James
Head of Government Affairs and Policy, GSK Australia
Dr. Kenneth Hartigan-Go
Honorary Visiting Associate Professor, National University of Singapore
The AP-CHAAI Secretariat
The Global Coalition on Aging (GCOA) serves as the Secretariat of the Asia-Pacific Consortium for Healthy Aging and Adult Immunization (AP-CHAAI). GCOA is the leading business voice on aging, working globally to reshape how societies and leaders approach the 21st century’s demographic shift. Bringing together corporations across diverse industries, GCOA combines strategic interests in aging populations with a comprehensive understanding of its economic and social implications.
Through rigorous research, policy analysis, advocacy, and strategic communications, GCOA advances innovative solutions to ensure that global aging is recognized as a driver of sustainable economic growth, social value creation, and wealth enhancement. As Secretariat, GCOA provides AP-CHAAI with strategic leadership, operational support, and a global perspective on aging, economics, and healthy aging.
Compliance and Independence
AP-CHAAI operates as an independent, expert-led consortium. The perspectives, analyses, and recommendations shared through our work reflect the views of our members and are not directed by any external partner. Our governance, outputs, and decisions are independent and driven by our Steering Committee and working groups. AP-CHAAI receives funding from partners such as GSK and Pfizer to support its activities.